Clinical trial
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
NCT02846545 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 26, 2016
- Completion date
- January 5, 2021
- Enrollment
- 84 (actual)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.